Genmab (GMAB) AGM 2021 summary
Event summary combining transcript, slides, and related documents.
AGM 2021 summary
26 Oct, 2026Opening remarks and agenda
Wholly virtual AGM held April 13, 2021, at 14:00 CET; the Chair reported on activities during the past year, the CEO presented 2021 plans, and the CFO presented the 2020 Annual Report.
Financial performance review
The 2020 Annual Report was approved; profit of DKK 4,758 million was transferred to retained earnings.
Board and executive committee updates
Deirdre P. Connelly, Pernille Erenbjerg, Rolf Hoffmann, Paolo Paoletti, Jonathan Peacock and Anders Gersel Pedersen were re-elected for one-year terms.
Discharge was given to the Board of Directors and Executive Management; PricewaterhouseCoopers was re-elected as auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genmab
- DKK 2,166 million of 2019 profit was retained as key AGM resolutions passed.GMAB
AGM 2020 - FY2021 accounts approved, DKK 3,008 million retained, and one new director elected.GMABAGM 2022
- AGM approved the 2022 accounts and adopted board, remuneration and treasury-share proposals.GMABAGM 2023
- 2023 accounts approved; directors re-elected and governance and capital proposals adopted.GMABAGM 2024
- Rina-S significantly improved PFS and OS in Phase 3 platinum-resistant ovarian cancer trial.GMABStudy result
- AbbVie collaboration pairs three bispecific programs with up to four discovery candidates.GMABCollaboration
- Proposed 2026 board pay combines cash fees, RSUs and committee meeting payments.GMABEGM 2026 presentation
- Pivotal phase III oncology readouts in Q4 2026 set up three major launches in 2027.GMABBank of America Global Healthcare Conference
- Rina-S® showed durable activity in gynecologic cancers, advancing toward Phase 3.GMABR&D Update